Genetics of Congenital Heart Disease: A Narrative Review of Recent Advances & Clinical Implications

Authors: Vikrant Mankar¹, Assistant Professor Dept. of Child Health Nursing
Dr. Vaishali Tendolkar² Principal Cum Professor Dept. Of Mental Health Nursing

Abstract

Congenital heart disease (CHD) is the most common human birth defect and remains a leading cause of mortality in childhood. The advances in clinical management have improved the survival of children with CHD; adult survivors commonly experience cardiac and non-cardiac comorbidities, which affect quality of life and prognosis. Therefore, the elucidation of genetic etiologies of CHD not only has important clinical implications for genetic counselling of patients and families but may also impact clinical outcomes by identifying at-risk patients. Recent advancements in genetic technologies including massively parallel sequencing, have allowed for the discovery of new genetic etiologies for CHD. They are variant prioritization and interpretation of pathogenicity remain challenges in the field of CHD genomics, advances in single-cell genomics and functional genomics using cellular and animal models of CHD have the potential to provide novel insights into the underlying mechanisms of CHD and its associated morbidities. In this review, we provide an updated summary of the established genetic contributors to CHD and discuss recent advances in our understanding of the genetic architecture of CHD along with current challenges with the interpretation of genetic variation. Furthermore, we highlight the clinical implications of genetic findings to predict and potentially improve clinical outcomes in patients with CHD.

Keywords: Congenital heart disease (CHD), genetics, genetic testing, clinical outcomes
Introduction

Congenital heart disease (CHD) is the most common birth defect, affecting nearly 1% of all live births. CHD encompasses a wide spectrum of defects from simple malformations with a favorable prognosis to more complex and severe lesions that require multiple catheter-based or surgical interventions with uncertain long-term outcomes. Although CHD remains a leading cause of morbidity and mortality in childhood, the population of adults with CHD is dramatically expanding. Now, more than 90% of children with CHD survive into adulthood due to significant advances in disease recognition and improved medical and surgical management across the lifespan. Therefore, understanding the genomic architecture of CHD is increasingly clinically important. While there have been significant advances in the elucidation of the genetic etiologies for other forms of inherited cardiac disease such as cardiomyopathy and arrhythmias, it has only been with the increased understanding of the molecular pathways regulating cardiovascular development over the past couple of decades that the genetic basis of CHD has become more defined. However, the detailed genetic architecture of CHD and how disruption of these underlying regulatory mechanisms results in the spectrum of CHD phenotypes is actively being investigated.

This narrative review was compiled through study, analysis, and discussion of previously published literature. PubMed was searched without time limitations and language restrictions, including articles related to the etiology and genetic contributors of CHD, NGS studies in large CHD cohorts, challenges with interpretation of NGS findings, functional genomics of CHD, and clinical implications of genetic testing and genetic prediction of clinical outcomes in patients with CHD. Search terms included congenital heart defects in combination with genetics, etiology, pathogenesis, mutations/genetic variation, environmental factors, NGS, exome sequencing, whole genome sequencing (WGS), variant prioritization, scRNA-seq, functional genomics, genetic animal models, human induced pluripotent stem cells (iPSCs), noncoding variants or genetic testing and a combination of congenital heart disease, genetics and clinical outcomes.

Established etiologic contributors to CHD

The etiology of CHD is multifactorial as both genetic and environmental factors have been implicated in its etiology. Specific genetic causes can be detected in an estimated 40% of CHD cases. Genetic causes of CHD are extremely heterogeneous, including chromosomal anomalies or aneuploidies (estimated 13%, range from 9% to 18%), copy number variants (CNVs) (estimated 10–15%: range from 3% to 25% in syndromic CHD and 3% to 10% in non-syndromic CHD), and single gene disorders (12%). The genetic basis of CHD can be divided into syndromic CHD and non-syndromic CHD, where congenital abnormalities are isolated to the heart.
They are established genetic causes of congenital heart disease. Chromosomal abnormalities, copy number variation and single gene variants are associated with ~40% of congenital heart disease cases but the majority (60%) of congenital heart disease remains unknown. All percentages are approximate based on recent publications. NR, not reported.

**Transcription factors**

Transcription factors involved in cardiac development have been identified by genetic studies with multiple animal model systems. NKX, GATA and T-box family members constitute the core regulatory network that is responsible for normal cardiogenesis and are causative genes in CHD.

Mutations in the homeobox transcription factor NKX2–5 were first reported as the cause of non-syndromic CHD by studying four kindreds with autosomal dominant disease. The common phenotype associated with NKX2–5 mutations is atrial septal defect (ASD) along with atrioventricular conduction abnormalities. NKX2–5 mutations have since been reported in a wide spectrum of CHD, including ventricular septal defect (VSD), tetralogy of Fallot (TOF), subvalvar aortic stenosis (AS), pulmonary atresia and hypoplastic left heart syndrome (HLHS), as well as atrioventricular conduction abnormalities, leading to complete heart block and sudden cardiac death. Previous studies demonstrated that mutations in the homeodomain of NKX2–5 are a case of ASD, while mutations outside the homeodomain may result in TOF. In addition, mice harboring NKX2–5 mutations have been reported to recapitulate cardiac phenotypes found in humans.
Identification of $NKX2-5$ mutations is clinically beneficial in terms of detecting patients with the increased risk of progressive conduction system disease, sudden cardiac death or asymptomatic ASD.

**Challenges with interpretation of NGS results**

Although NGS technologies in CHD cohorts have contributed to identifying variants associated with CHD risk, NGS techniques have some challenges that have limited translation to the clinical setting. First, there are difficulties in variant prioritization and interpretation. Second, establishing the pathogenicity of identified variants is still challenging even with advances in *in vitro* and *in vivo* genetic modelling of CHD. Third, with the increased availability and use of WGS, the role of noncoding variation in the genetic architecture of CHD is not clear.

**Clinical implications of recent genetic advances**

**Genetic testing**

Over the past 20 years, the advanced genetic testing methodologies (e.g., CMA and exome sequencing) are increasingly being incorporated into the genetic evaluation of patients with CHD, and the results of this testing has important clinical implications. The clinical benefits of genetic testing for patients with CHD include establishing a genetic diagnosis, anticipatory management of CHD and associated extra-cardiac conditions, and clinical screening of at-risk family members. In addition, genetic testing can provide the information about the genetic causes and the recurrence risk of CHD to support reproductive decisions and to guide perinatal management. While CMA and single-gene testing for specific syndromes are currently utilized as standard genetic testing for patients with CHD and extra-cardiac abnormalities, diagnostic use of NGS technology is allowing the interrogation of large datasets of genetic variants. The overall diagnostic yield of genetic testing varies from the low single digits to close to 40% which depends on the tests available the anatomical lesions, and the presence of extra-cardiac or other relevant clinical features. Despite the potential utility variant interpretation is challenging as genotype-phenotype correlations remain elusive and phenotypic heterogeneity or incomplete penetrance is present. Communicating complex genetic findings to potentially unsuspecting patients is also challenging. Given the potential psychosocial impact of genetic testing in asymptomatic, phenotype-negative individuals, it is therefore critical that genetic testing should be offered within the context of appropriate genetic counselling so that families are given the opportunity to discuss insurance and other risks well in advance.
Genetic prediction of clinical outcomes

Despite advances in our understanding of genetics underlying CHD, prediction of clinical outcomes by using genetic findings remains challenging. Initial successful examples of linking common genetic variants for clinical care were limited to areas of prediction of disease risk, disease classification, and drug response. Apolipoprotein E genotypes were associated with adverse neurodevelopmental outcomes after cardiac surgery in patients with CHD. Additionally, in patients with single ventricle, adrenergic receptor genotypes were associated with poor postoperative outcomes, and renin-angiotensin-aldosterone receptor genotypes were linked to failure of ventricular remodeling after surgery, impaired renal function and somatic growth.

Bibliography

1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39:1890-900. 10.1016/S0735-1097(02)01886-

2. Boneva RS, Botto LD, Moore CA, et al. Mortality associated with congenital heart defects in the United States: trends and racial disparities, 1979-1997. Circulation 2001; 103:2376-81. 10.1161/01.CIR.103.19.2376

3. Gilboa SM, Salemi JL, Nembhard WN, et al. Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006. Circulation 2010; 122:2254-63. 10.1161/CIRCULATIONAHA.110.947002

4. Khairy P, Ionescu-Ittu R, Mackie AS, et al. Changing mortality in congenital heart disease. J Am Coll Cardiol 2010; 56:1149-57. 10.1016/j.jacc.2010.03.085

5. Raissadati A, Nieminen H, Jokinen E, et al. Progress in late results among pediatric cardiac surgery patients: a population-based 6-decade study with 98% follow-up. Circulation 2015; 131:347-53; discussion 353. 10.1161/CIRCULATIONAHA.114.011190

6. Mital S, Musunuru K, Garg V, et al. Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement from the American Heart Association. Circ Cardiovasc Genet 2016; 9:448-67. 10.1161/HCG.

7. Garg V. Insights into the genetic basis of congenital heart disease. Cell Mol Life Sci 2006; 63:1141-8. 10.1007/s00018-005-5532-2

8. Richards AA, Garg V. Genetics of congenital heart disease. Curr Cardiol Rev 2010;6:91-7. 10.2174/157340310791162703

9. Zaidi S, Brueckner M. Genetics and Genomics of Congenital Heart Disease. Circ Res 2017;120:923-40. 10.1161/CIRCRESAHA.116.309140

10. Pierpont ME, Brueckner M, Chung WK, et al. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation 2018;138:e653-711. 10.1161/CIR.
11. Sifrim A, Hitz MP, Wilsdon A, et al. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. Nat Genet 2016;48:1060-5. 10.1038/ng.3627

12. Cowan JR, Ware SM. Genetics and genetic testing in congenital heart disease. Clin Perinatol 2015;42:373-93, ix. 10.1016/j.clp.2015.02.009

13. Hartman RJ, Rasmussen SA, Botto LD, et al. The contribution of chromosomal abnormalities to congenital heart defects: a population-based study. Pediatr Cardiol 2011;32:1147-57. 10.1007/s00246-011-0034-5

14. Carey AS, Liang L, Edwards J, et al. Effect of copy number variants on outcomes for infants with single ventricle heart defects. Cardiovasc Genet 2013;6:444-51. 10.1161/CIRCGENETICS.113.

15. Kim DS, Kim JH, Burt AA, et al. Burden of potentially pathologic copy number variants is higher in children with isolated congenital heart disease and significantly impairs covariate-adjusted transplant-free survival. J Thorac Cardiovasc Surg 2016;151:1147-51.e4. 10.1016/j.jtcvs.2015.09.136

16. Glessner JT, Bick AG, Ito K, et al. Increased frequency of de novo copy number variants in congenital heart disease by integrative analysis of single nucleotide polymorphism array and exome sequence data. Circ Res 2014;115:884-96. 10.1161/CIRCRESAHA.115.

27. Homsy J, Zaidi S, Shen Y, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science 2015;350:1262-6. 10.1126/science.aac9396

28. Schott JJ, Benson DW, Basson CT, et al. Congenital heart disease caused by mutations in the transcription factor NKX2.5. Science 1998;281:108-11. 10.1126/science.281.5373.108

29. Benson DW, Silberbach GM, Kavanaugh-McHugh A, et al. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest 1999;104:1567-73. 10.1172/jci18333

30. Goldmuntz E, Geiger E, Benson DW. NKX2.5 mutations in patients with tetralogy of fallot. Circulation 2001;104:2565-8. 10.1161/hc4601.098427

31. McElhinney DB, Geiger E, Blinder J, et al. NKX2.5 mutations in patients with congenital heart disease. J Am Coll Cardiol 2003;42:1650-5. 10.1016/j.jacc.2003.05.004

32. Stallmeyer B, Fenge H, Nowak-Göttl U, et al. Mutational spectrum in the cardiac transcription factor gene NKX2.5 (CSX) associated with congenital heart disease. Clin Genet 2010;78:533-40. 10.1111/j.1399-0004.2010.01422.x

33. Ellesøe SG, Johansen MM, Bjerre JV, et al. Familial Atrial Septal Defect and Sudden Cardiac Death: Identification of a Novel NKX2-5 Mutation and a Review of the Literature. Congenit Heart Dis 2016;11:283-90. 10.1111/chd.12317
34. Olson EN. Gene regulatory networks in the evolution and development of the heart. Science 2006;313:1922-7. 10.1126/science.1132292

35. Kodo K, Nishizawa T, Furutani M, et al. Genetic analysis of essential cardiac transcription factors in 256 patients with non-syndromic congenital heart defects. Circ J 2012;76:1703-11. 10.1253/circj.CJ-11-1389

36. Srivastava D. Genetic regulation of cardiogenesis and congenital heart disease. Annu Rev Pathol 2006;1:199-213. 10.1146/annurev.pathol.1.110304.100039

37. Akçaboy MI, Cengiz FB, Inceoğlu B, et al. The effect of p.Arg25Cys alteration in NKX2-5 on conotruncal heart anomalies: mutation or polymorphism? Pediatr Cardiol 2008;29:126-9. 10.1007/s00246-007-9058-2

38. Biben C, Weber R, Kesteven S, et al. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res 2000;87:888-95. 10.1161/01.RES.87.10.888

39. Ashraf H, Pradhan L, Chang EI, et al. A mouse model of human congenital heart disease: high incidence of diverse cardiac anomalies and ventricular noncompaction produced by heterozygous Nkx2-5 homeodomain missense mutation. Circ Cardiovasc Genet 2014;7:423-33. 10.1161/CIRCGENETICS.113.000281

40. Landis BJ, Ware SM. The Current Landscape of Genetic Testing in Cardiovascular Malformations: Opportunities and Challenges. Front Cardiovasc Med 2016;3:22. 10.3389/fcvm.2016.00022

41. Manolio TA. Bringing genome-wide association findings into clinical use. Nat Rev Genet 2013;14:549-58. 10.1038

42. Gaynor JW, Gerdes M, Zackai EH, et al. Apolipoprotein E genotype and neurodevelopmental sequelae of infant cardiac surgery. J Thorac Cardiovasc Surg 2003;126:1736-45. 10.1016/S0022-5223(03)01188-7

43. Gaynor JW, Kim DS, Arrington CB, et al. Validation of association of the apolipoprotein E ε2 allele with neurodevelopmental dysfunction after cardiac surgery in neonates and infants. J Thorac Cardiovasc Surg 2014;148:2560-6. 10.1016/j.jtcvs.2014.07.052

44. Mital S, Chung WK, Colan SD, et al. Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. Circulation 2011;123:2353-62. 10.1161/CIRCULATIONAHA.110.004341